Volume | 173,928 |
|
|||||
News | - | ||||||
Day High | 3.72 | Low High |
|||||
Day Low | 3.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.56 | 3.45 | 3.72 | 3.45 | 3.50 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,096 | 173,928 | $ 3.55 | $ 618,270 | - | 1.28 - 4.2684 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 6,291 | $ 3.45 | USD |
Galectin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
213.38M | 61.85M | - | 0 | -44.81M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galectin Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.34 | 3.72 | 2.88 | 3.30 | 224,287 | 0.11 | 3.29% |
1 Month | 2.39 | 4.2684 | 2.26 | 3.56 | 322,270 | 1.06 | 44.35% |
3 Months | 1.74 | 4.2684 | 1.59 | 3.05 | 159,654 | 1.71 | 98.28% |
6 Months | 2.07 | 4.2684 | 1.555 | 2.66 | 107,750 | 1.38 | 66.67% |
1 Year | 1.76 | 4.2684 | 1.28 | 2.33 | 81,553 | 1.69 | 96.02% |
3 Years | 4.00 | 5.70 | 1.02 | 3.23 | 331,826 | -0.55 | -13.75% |
5 Years | 4.75 | 5.70 | 1.02 | 3.03 | 399,415 | -1.30 | -27.37% |
Galectin Therapeutics Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |